Cargando…

Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies

Daratumumab has proven to be highly efficacious for relapsed and refractory multiple myeloma (MM) and has recently been approved in the frontline setting for MM patients ineligible for transplantation. In the future, expanded indications are possible for daratumumab and other anti-CD38 monoclonal an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lancman, Guido, Arinsburg, Suzanne, Jhang, Jeffrey, Cho, Hearn Jay, Jagannath, Sundar, Madduri, Deepu, Parekh, Samir, Richter, Joshua, Chari, Ajai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249335/ https://www.ncbi.nlm.nih.gov/pubmed/30498492 http://dx.doi.org/10.3389/fimmu.2018.02616

Ejemplares similares

Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2021)

Phase 1b trial of isatuximab, an anti‐CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
por: Martin, Thomas G., et al.
Publicado: (2021)

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
por: Wang, Bo, et al.
Publicado: (2020)

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
por: Wang, Bo, et al.
Publicado: (2020)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications
por: Bhalla, Sherry, et al.
Publicado: (2021)

MM-239: A Tertiary Center Experience of Multiple Myeloma Patients with COVID-19: Lessons Learned and the Path Forward
por: Wang, Bo, et al.
Publicado: (2020)

Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach
por: Laganà, Alessandro, et al.
Publicado: (2018)

Targeting Nuclear Export Proteins in Multiple Myeloma Therapy
por: Theodoropoulos, Nicholas, et al.
Publicado: (2020)

MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21(Cip1)
por: Mei, Anna Huo-Chang, et al.
Publicado: (2020)

Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma
por: Mouhieddine, Tarek H., et al.
Publicado: (2022)

Transfusion management for patients taking an anti-CD38 monoclonal antibody
por: Bub, Carolina Bonet, et al.
Publicado: (2018)

Proteasome inhibition and its therapeutic potential in multiple myeloma
por: Chari, Ajai, et al.
Publicado: (2010)

OAB-048: Suboptimal humoral immune response to SARS-CoV-2 mRNA vaccination in myeloma patients is associated with anti-CD38 mAb and BCMA-targeted treatment
por: Oekelen, Oliver Van, et al.
Publicado: (2021)

The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution
por: Bonomo, Lauren, et al.
Publicado: (2016)

Review: Effects of anti‐CD38 monoclonal antibodies on red blood cell transfusion and interventions
por: Song, Jia, et al.
Publicado: (2021)

Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment
por: Van Oekelen, Oliver, et al.
Publicado: (2021)

B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies
por: Sanchez, Larysa, et al.
Publicado: (2021)

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
por: Roccatello, Dario, et al.
Publicado: (2020)

COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
por: van de Donk, Niels W. C. J., et al.
Publicado: (2016)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

NP-114: Lesson Learned: Management of patients with Multiple Myeloma (MM) and their response to two doses of COVID-19 RNA vaccine
por: Verina, Daniel, et al.
Publicado: (2021)

Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
por: Wu, Hao-Tian, et al.
Publicado: (2022)

Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report
por: Madduri, D., et al.
Publicado: (2021)

P915: TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI-CD38 MONOCLONAL ANTIBODY: FINDINGS FROM THE CONNECT MM DISEASE REGISTRY
por: Abonour, Rafat, et al.
Publicado: (2023)

Management of Patients With Hepatitis C Virus, Monoclonal Gammopathy of Undetermined Significance, and Multiple Myeloma
por: Hannaford, Alisse, et al.
Publicado: (2017)

Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
por: Van Oekelen, Oliver, et al.
Publicado: (2021)

COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers
por: Hultcrantz, Malin, et al.
Publicado: (2020)

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2016)

De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment
por: Fotiou, Despina, et al.
Publicado: (2021)

Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies
por: Mustafa, Nurulhuda, et al.
Publicado: (2022)

Mycophenolate Mofetil and Plasmapheresis: A Treatment Option for Severe Insulin Resistance caused by Insulin Antibodies
por: Brooks, Danielle, et al.
Publicado: (2021)

Massive transfusion in paediatric trauma: a single-centre experience
por: Hearn, R, et al.
Publicado: (2010)

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
por: Steinhardt, Maximilian Johannes, et al.
Publicado: (2020)

P828: EFFECT OF ANTI-CD38 MONOCLONAL ANTIBODIES ON THE INTERACTION OF MYELOMA CELLS WITH BONE MARROW STROMAL CELLS
por: Lienhart, Malgorzata, et al.
Publicado: (2023)

Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring
por: Chari, Ajai, et al.
Publicado: (2014)

NS-64: Lessons learned: patient management and outcomes of Multiple Myeloma patients during the COVID-19 pandemic in New York City
por: Catamero, Donna, et al.
Publicado: (2021)

Anti‐CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping
por: Chami, Btissam, et al.
Publicado: (2022)

CD38 in Neurodegeneration and Neuroinflammation
por: Guerreiro, Serge, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_46tvlpb7clrpc6a4bmtgd3rv7a